Veana Therapeutics secures NIH funding for VIMO

Veana Therapeutics is pleased to announce a Phase I Small Business Innovation Research (SBIR) grant award from the NIH National Cancer Institute to conduct proof-of-concept pre-clinical studies of its lead product, VIMO (Veana Immune Modulator) in combination with immune checkpoint inhibitors in triple negative breast cancer. Learn more about Veana here.

2018-11-12T11:27:32+00:00